secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2026-06-11T11:06:57+00:00
Accession:  0001549595-26-000034
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix reports Phase 1a/1b data for bexobrutideg: ORR 83% in R/R CLL, 92.9% in earlier-line
--------------------------------------------------------------------------------

- Phase 1a ORR 83.0% (47 evaluable), median PFS 22.1 months; median 4 prior lines.
- Phase 1b Cohort 5 (BTKi-treated, BCL2i-naïve): ORR 92.9% at 5.2 months follow-up; 18/19 on treatment.
- Phase 1b Cohort 15 (BTKi-naïve, incl. treatment-naïve): ORR 84.2% at 4.9 months; 19/20 on treatment.
- Safety: well-tolerated, no dose-limiting toxicities, no treatment-related Grade 5 events; AE discontinuation 5.6%.
- Company plans Phase 3 monotherapy program and has Roche collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000034/0001549595-26-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000034/nrix-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001549595-26-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer